# SKYCLARYS® (omaveloxolone) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/omaveloxolone

> The FDA approved SKYCLARYS® (omaveloxolone), sponsored by BIOGEN INC. (BIIB), on Sep 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SKYCLARYS® (omaveloxolone) |
| Codes |  |
| Sponsor | BIOGEN INC. (BIIB) https://sec-api.dev/companies/biib/catalysts |
| Indications | [children and adults living with fa](https://sec-api.dev/indications/children-and-adults-living-with-fa), To treat Friedrich’s ataxia, [Friedreich Ataxia](https://sec-api.dev/indications/friedreich-ataxia) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### February 28, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat Friedrich’s ataxia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Skyclarys | omaveloxolone | 2/28/2023 | To treat Friedrich’s ataxiaDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA216718 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230228, review_priority PRIORITY; sponsor_name BIOGEN US; product SKYCLARYS (OMAVELOXOLONE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216718%22

### Sep 2023: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-12, last confirmed 2026-02-06.
- SEC Form 10-K (accession 0000875045-26-000013): "As part of our acquisition of Reata in September 2023 we obtained a rare pediatric disease PRV in connection with the approval of SKYCLARYS, which was approved by the FDA in February 2023." https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm
- SEC Form 10-K (accession 0000875045-25-000009): "As part of our acquisition of Reata in September 2023 we obtained a rare pediatric disease PRV in connection with the approval of SKYCLARYS, which was approved by the FDA in February 2023." https://www.sec.gov/Archives/edgar/data/875045/000087504525000009/biib-20241231.htm

### December 20, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA216718 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority STANDARD; sponsor_name BIOGEN US; product SKYCLARYS (OMAVELOXOLONE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216718%22

### August 19, 2025: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: children and adults living with FA.
- First seen 2025-03-24, last confirmed 2025-03-24.
- SEC Form 10-K (accession 0000950170-25-043925): "The FDA has accepted for filing PTC's NDA for vatiquinone for the treatment of children and adults living with FA with a target action date of August 19, 2025." https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Friedreich Ataxia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06953583 (A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Biogen." https://clinicaltrials.gov/study/NCT06953583

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Friedreich Ataxia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06953583 (A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Biogen." https://clinicaltrials.gov/study/NCT06953583

## Same indication

- [Nomlabofusp](https://sec-api.dev/pdufa/nomlabofusp) (LRMR)
- [Vatiquinone](https://sec-api.dev/pdufa/vatiquinone) (PTCT)

Calendar months: [August 2025](https://sec-api.dev/fda-calendar/2025-08), [November 2027](https://sec-api.dev/fda-calendar/2027-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/omaveloxolone.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SKYCLARYS® (omaveloxolone) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/omaveloxolone

```bibtex
@misc{secapidev_pdufa_omaveloxolone_20261116,
  title        = {SKYCLARYS® (omaveloxolone) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/omaveloxolone}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_omaveloxolone_20261116","title":"SKYCLARYS® (omaveloxolone) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/omaveloxolone","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
